1.Virtual lymph node analysis to evaluate axillary lymph node coverage provided by tangential breast irradiation.
Shin Hyung PARK ; Jae Chul KIM ; Jeong Eun LEE ; In Kyu PARK
Radiation Oncology Journal 2015;33(1):50-56
PURPOSE: To investigate the coverage of axillary lymph node with tangential breast irradiation fields by using virtual lymph node (LN) analysis. MATERIALS AND METHODS: Forty-eight women who were treated with whole breast irradiation after breast-conserving surgery were analyzed. The axillary and breast volumes were delineated according to the Radiation Therapy Oncology Group (RTOG) contouring atlas. To generate virtual LN contours, preoperative fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) scans with identifiable LN were fused with the CT scans, and the virtual LN contour were delineated on the CT. RESULTS: The median level I and II axillary volume coverage percentages at the VD95% line were 33.5% (range, 5.3% to 90.4%) and 0.6% (range, 0.0% to 14.6%), respectively. Thirty-one LNs in 18 patients were delineated (26 in level I and 5 in level II). In the level I axilla, 84.6% of virtual LNs were encompassed by the 95% isodose line. In the level II axilla, by contrast, none of the virtual LNs were encompassed by the 95% isodose volumes. There was a substantial discrepancy between the RTOG contouring atlas-based axillary volume analysis and the virtual LN analysis, especially for the level I axillary coverage. The axillary volume coverage was associated with the body mass index (BMI) and breast volume. CONCLUSION: The tangential breast irradiation did not deliver adequate therapeutic doses to the axillary region, particularly those in the level II axilla. Patients with small breast volumes or lower BMI showed reduced axillary coverage from the tangential breast fields. For axillary LN irradiation, individualized anatomy-based radiation fields for patients would be necessary.
Axilla
;
Body Mass Index
;
Breast Neoplasms
;
Breast*
;
Electrons
;
Female
;
Humans
;
Lymph Nodes*
;
Mastectomy, Segmental
;
Radiotherapy
;
Tomography, X-Ray Computed
2.New methods for optical distance indicator and gantry angle quality control tests in medical linear accelerators: image processing by using a 3D phantom.
Mahdi Heravian SHANDIZ ; Ghorban Safaeian LAYEN ; Kazem ANVARI ; Mohammadmahdi KHALILZADEH
Radiation Oncology Journal 2015;33(1):42-49
PURPOSE: In order to keep the acceptable level of the radiation oncology linear accelerators, it is necessary to apply a reliable quality assurance (QA) program. MATERIALS AND METHODS: The QA protocols, published by authoritative organizations, such as the American Association of Physicists in Medicine (AAPM), determine the quality control (QC) tests which should be performed on the medical linear accelerators and the threshold levels for each test. The purpose of this study is to increase the accuracy and precision of the selected QC tests in order to increase the quality of treatment and also increase the speed of the tests to convince the crowded centers to start a reliable QA program. A new method has been developed for two of the QC tests; optical distance indicator (ODI) QC test as a daily test and gantry angle QC test as a monthly test. This method uses an image processing approach utilizing the snapshots taken by the CCD camera to measure the source to surface distance (SSD) and gantry angle. RESULTS: The new method of ODI QC test has an accuracy of 99.95% with a standard deviation of 0.061 cm and the new method for gantry angle QC has a precision of 0.43degrees. The automated proposed method which is used for both ODI and gantry angle QC tests, contains highly accurate and precise results which are objective and the human-caused errors have no effect on the results. CONCLUSION: The results show that they are in the acceptable range for both of the QC tests, according to AAPM task group 142.
Particle Accelerators*
;
Quality Control*
;
Radiation Oncology
3.Post-treatment intracranial hemorrhage of brain metastases from hepatocellular carcinoma.
Kyung Su KIM ; Kyubo KIM ; Eui Kyu CHIE ; Yoon Jun KIM ; Jung Hwan YOON ; Hyo Suk LEE ; Sung W HA
Radiation Oncology Journal 2015;33(1):36-41
PURPOSE: To evaluate the incidence and risk factors of post-treatment intracranial hemorrhage of brain metastases from hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Medical records of 81 patients who have been diagnosed of brain metastases from HCC and underwent surgery, radiosurgery and/or whole brain radiotherapy (WBRT) between January 2000 and December 2013 were retrospectively reviewed. RESULTS: Intracranial hemorrhage was present in 64 patients (79%) at the time of diagnosis. Median value of alpha-fetoprotein (AFP) level was 1,700 ng/mL. The Eastern Cooperative Oncology Group (ECOG) performance status for 20 patients was greater than 2. Fifty-seven patients underwent WBRT and the others were treated with surgery and/or radiosurgery without WBRT. During follow-up, 12 events of intracranial hemorrhage after treatment were identified. Three-month post-treatment hemorrhage rate was 16.1%. Multivariate analyses revealed that ECOG performance status, AFP, and WBRT were associated with post-treatment hemorrhage (p = 0.013, 0.013, and 0.003, respectively). Kaplan-Meier analysis showed that 3-month post-treatment hemorrhage rate of new lesion was higher in patients treated without WBRT, although statistical significance was not reached. (18.6% vs. 4.6%; p = 0.104). Ten of 12 patients with post-treatment hemorrhage died with neurologic cause. CONCLUSION: WBRT should be considered to prevent post-treatment hemorrhage in the treatment of brain metastases from HCC.
alpha-Fetoproteins
;
Brain*
;
Carcinoma, Hepatocellular*
;
Diagnosis
;
Follow-Up Studies
;
Hemorrhage
;
Humans
;
Incidence
;
Intracranial Hemorrhages*
;
Kaplan-Meier Estimate
;
Medical Records
;
Multivariate Analysis
;
Neoplasm Metastasis*
;
Radiosurgery
;
Radiotherapy
;
Retrospective Studies
;
Risk Factors
4.Outcome analysis in patients with uterine sarcoma.
Tosol YU ; Hak Jae KIM ; Hong Gyun WU ; Sung Whan HA ; Yong Sang SONG ; Noh Hyun PARK ; Jae Won KIM
Radiation Oncology Journal 2015;33(1):29-35
PURPOSE: To analyze the prognostic factors for survivals and to evaluate the impact of postoperative whole pelvic radiotherapy (WPRT) on pelvic failure in patients with uterine sarcoma treated with radical surgery. MATERIALS AND METHODS: We retrospectively analyzed 75 patients with uterine sarcoma who underwent radical surgery with (n = 22) or without (n = 53) radiotherapy between 1990 and 2010. There were 23 and 52 patients with carcinosarcoma and non-carcinosarcoma (leiomyosarcoma, 22; endometrial stromal sarcoma, 25; others, 5), respectively. The median follow-up period was 64 months (range, 17 to 269 months). RESULTS: The 5-year overall survival (OS) and pelvic failure-free survival (PFFS) of total patients was 64.2% and 83.4%, respectively. Multivariate analysis revealed that mitotic count (p = 0.006) was a significant predictor of OS. However, factors were not found to be associated with PFFS. On analyzing each of the histologic subtypes separately, postoperative WPRT significantly reduced pelvic failure in patients with carcinosarcoma (10.0% vs. 53.7%; p = 0.046), but not in patients with non-carcinosarcoma (12.5% vs. 9.9%; p = 0.866). Among the patients with carcinosarcoma, 4 patients (17%) had recurrence within the pelvis and 3 patients (13%) had recurrence in other sites as an initial failure, whereas among the patients with non-carcinosarcoma, 3 patients (6%) experienced pelvic failure and 13 patients (25%) experienced distant failure. CONCLUSION: The most significant predictor of OS was mitotic count. Based on the improved PFFS after postoperative WPRT only in patients with carcinosarcoma and the difference in patterns of failure between histologic subtypes, optimal adjuvant treatment options should be offered to patients based on the risk of recurrence patterns.
Carcinosarcoma
;
Follow-Up Studies
;
Humans
;
Multivariate Analysis
;
Pelvis
;
Radiotherapy
;
Radiotherapy, Adjuvant
;
Recurrence
;
Retrospective Studies
;
Sarcoma*
;
Sarcoma, Endometrial Stromal
;
Uterus
5.Clinical and biochemical outcomes of men undergoing radical prostatectomy or radiation therapy for localized prostate cancer.
David SCHREIBER ; Justin RINEER ; Jeffrey P WEISS ; Joseph SAFDIEH ; Joseph WEINER ; Marvin ROTMAN ; David SCHWARTZ
Radiation Oncology Journal 2015;33(1):21-28
PURPOSE: We analyzed outcomes of patients with prostate cancer undergoing either radical retropubic prostatectomy (RRP) +/- salvage radiation or definitive radiation therapy (RT) +/- androgen deprivation. MATERIALS AND METHODS: From 2003-2010 there were 251 patients who underwent RRP and 469 patients who received RT (> or =7,560 cGy) for prostate cancer. Kaplan-Meier analysis was performed with the log-rank test to compare biochemical control (bCR), distant metastatic-free survival (DMPFS), and prostate cancer-specific survival (PCSS) between the two groups. RESULTS: The median follow-up was 70 months and 61.3% of the men were African American. For low risk disease the 6-year bCR were 90.3% for RT and 85.6% for RRP (p = 0.23) and the 6-year post-salvage bCR were 90.3% vs. 90.9%, respectively (p = 0.84). For intermediate risk disease the 6-year bCR were 82.6% for RT and 59.7% for RRP (p < 0.001) and 82.6% vs. 74.0%, respectively, after including those salvaged with RT (p = 0.06). For high risk disease, the 6-year bCR were 67.4% for RT and 41.3% for RRP (p < 0.001) and after including those salvaged with RT was 67.4% vs. 43.1%, respectively (p < 0.001). However, there were no significant differences between the two groups in regards to DMPFS or PCSS. CONCLUSION: Treatment approaches utilizing RRP +/- salvage radiation or RT +/- androgen deprivation yielded equivalent DMPFS and PCSS outcomes. Biochemical control rates, using their respective definitions, appeared equivalent or better in those who received treatment with RT.
Follow-Up Studies
;
Humans
;
Kaplan-Meier Estimate
;
Male
;
Prostate
;
Prostatectomy*
;
Prostatic Neoplasms*
6.Treatment outcomes of neoadjuvant concurrent chemoradiotherapy followed by esophagectomy for patients with esophageal cancer.
Yong Hyub KIM ; Sang Yun SONG ; Hyun Jeong SHIM ; Woong Ki CHUNG ; Sung Ja AHN ; Mee Sun YOON ; Jae Uk JEONG ; Ju Young SONG ; Taek Keun NAM
Radiation Oncology Journal 2015;33(1):12-20
PURPOSE: To evaluate treatment outcomes and determine prognostic factors in patients with esophageal cancer treated with esophagectomy after neoadjuvant chemoradiotherapy (NCRT). MATERIALS AND METHODS: We retrospectively evaluated 39 patients with esophageal cancer who underwent concurrent chemoradiotherapy followed by esophagectomy between 2002 and 2012. Initial clinical stages of patients were stage IB in 1 patient (2.6%), stage II in 5 patients (12.9%), and stage III in 33 patients (84.6%). RESULTS: The median age of all the patients was 62 years, and the median follow-up period was 17 months. The 3-year overall survival (OS) rate was 33.6% in all the patients. The 3-year locoregional recurrence-free survival (LRFS) rate was 33.7%. In multivariate analysis with covariates of age, the Eastern Cooperative Oncology Group performance status, hypertension, diabetes mellitus, tumor length, clinical response, clinical stage, pathological response, pathological stage, lymphovascular invasion, surgical type, and radiotherapy to surgery interval, only pathological stage was an independent significant prognostic factor affecting both OS and LRFS. The complications in postoperative day 90 were pneumonia in 9 patients, anastomotic site leakage in 3 patients, and anastomotic site stricture in 2 patients. Postoperative 30-day mortality rate was 10.3% (4/39); the cause of death among these 4 patients was respiratory failure in 3 patients and myocardial infarction in one patient. CONCLUSION: Only pathological stage was an independent prognostic factor for both OS and LRFS in patients with esophageal cancer treated with esophagectomy after NCRT. We could confirm the significant role of NCRT in downstaging the initial tumor bulk and thus resulting in better survival of patients who gained earlier pathological stage after NCRT.
Cause of Death
;
Chemoradiotherapy*
;
Constriction, Pathologic
;
Diabetes Mellitus
;
Esophageal Neoplasms*
;
Esophagectomy*
;
Follow-Up Studies
;
Humans
;
Hypertension
;
Mortality
;
Multivariate Analysis
;
Myocardial Infarction
;
Neoadjuvant Therapy
;
Pneumonia
;
Radiotherapy
;
Respiratory Insufficiency
;
Retrospective Studies
7.Contemporary treatment with radiosurgery for spine metastasis and spinal cord compression in 2015.
Samuel RYU ; Hannah YOON ; Alexander STESSIN ; Fred GUTMAN ; Arthur ROSIELLO ; Raphael DAVIS
Radiation Oncology Journal 2015;33(1):1-11
With the progress of image-guided localization, body immobilization system, and computerized delivery of intensity-modulated radiation delivery, it became possible to perform spine radiosurgery. The next question is how to translate the high technology treatment to the clinical application. Clinical trials have been performed to demonstrate the feasibility of spine radiosurgery and efficacy of the treatment in the setting of spine metastasis, leading to the randomized trials by a cooperative group. Radiosurgery has also demonstrated its efficacy to decompress the spinal cord compression in selected group of patients. The experience indicates that spine radiosurgery has a potential to change the clinical practice in the management of spine metastasis and spinal cord compression.
Humans
;
Immobilization
;
Neoplasm Metastasis*
;
Radiosurgery*
;
Spinal Cord Compression*
;
Spine*
8.Neck muscle atrophy and soft-tissue fibrosis after neck dissection and postoperative radiotherapy for oral cancer.
Jinu KIM ; Eun Seow SHIN ; Jeong Eon KIM ; Sang Pil YOON ; Young Suk KIM
Radiation Oncology Journal 2015;33(4):344-349
Late complications of head and neck cancer survivors include neck muscle atrophy and soft-tissue fibrosis. We present an autopsy case of neck muscle atrophy and soft-tissue fibrosis (sternocleidomastoid, omohyoid, digastric, sternohyoid, sternothyroid, and platysma muscles) within the radiation field after modified radical neck dissection type I and postoperative radiotherapy for floor of mouth cancer. A 70-year-old man underwent primary tumor resection of the left floor of mouth, left marginal mandibulectomy, left modified radical neck dissection type I, and reconstruction with a radial forearm free flap. The patient received adjuvant radiotherapy. The dose to the primary tumor bed and involved neck nodes was 63 Gy in 35 fractions over 7 weeks. Areas of subclinical disease (left lower neck) received 50 Gy in 25 fractions over 5 weeks. Adjuvant chemotherapy was not administered.
Aged
;
Atrophy*
;
Autopsy
;
Chemotherapy, Adjuvant
;
Fibrosis*
;
Forearm
;
Free Tissue Flaps
;
Head and Neck Neoplasms
;
Humans
;
Mouth Floor
;
Mouth Neoplasms*
;
Neck Dissection*
;
Neck Muscles*
;
Neck*
;
Radiotherapy*
;
Radiotherapy, Adjuvant
;
Survivors
9.The first private-hospital based proton therapy center in Korea; status of the Proton Therapy Center at Samsung Medical Center.
Kwangzoo CHUNG ; Youngyih HAN ; Jinsung KIM ; Sung Hwan AHN ; Sang Gyu JU ; Sang Hoon JUNG ; Yoonsun CHUNG ; Sungkoo CHO ; Kwanghyun JO ; Eun Hyuk SHIN ; Chae Seon HONG ; Jung Suk SHIN ; Seyjoon PARK ; Dae Hyun KIM ; Hye Young KIM ; Boram LEE ; Gantaro SHIBAGAKI ; Hideki NONAKA ; Kenzo SASAI ; Yukio KOYABU ; Changhoon CHOI ; Seung Jae HUH ; Yong Chan AHN ; Hong Ryull PYO ; Do Hoon LIM ; Hee Chul PARK ; Won PARK ; Dong Ryul OH ; Jae Myung NOH ; Jeong Il YU ; Sanghyuk SONG ; Ji Eun LEE ; Bomi LEE ; Doo Ho CHOI
Radiation Oncology Journal 2015;33(4):337-343
PURPOSE: The purpose of this report is to describe the proton therapy system at Samsung Medical Center (SMC-PTS) including the proton beam generator, irradiation system, patient positioning system, patient position verification system, respiratory gating system, and operating and safety control system, and review the current status of the SMC-PTS. MATERIALS AND METHODS: The SMC-PTS has a cyclotron (230 MeV) and two treatment rooms: one treatment room is equipped with a multi-purpose nozzle and the other treatment room is equipped with a dedicated pencil beam scanning nozzle. The proton beam generator including the cyclotron and the energy selection system can lower the energy of protons down to 70 MeV from the maximum 230 MeV. RESULTS: The multi-purpose nozzle can deliver both wobbling proton beam and active scanning proton beam, and a multi-leaf collimator has been installed in the downstream of the nozzle. The dedicated scanning nozzle can deliver active scanning proton beam with a helium gas filled pipe minimizing unnecessary interactions with the air in the beam path. The equipment was provided by Sumitomo Heavy Industries Ltd., RayStation from RaySearch Laboratories AB is the selected treatment planning system, and data management will be handled by the MOSAIQ system from Elekta AB. CONCLUSION: The SMC-PTS located in Seoul, Korea, is scheduled to begin treating cancer patients in 2015.
Cyclotrons
;
Helium
;
Humans
;
Korea*
;
Metallurgy
;
Particle Accelerators
;
Patient Positioning
;
Proton Therapy*
;
Protons*
;
Radiation Oncology
;
Respiratory System
;
Seoul
10.Met inactivation by S-allylcysteine suppresses the migration and invasion of nasopharyngeal cancer cells induced by hepatocyte growth factor.
Oyeon CHO ; Hye Sook HWANG ; Bok Soon LEE ; Young Taek OH ; Chul Ho KIM ; Mison CHUN
Radiation Oncology Journal 2015;33(4):328-336
PURPOSE: Past studies have reported that S-allylcysteine (SAC) inhibits the migration and invasion of cancer cells through the restoration of E-cadherin, the reduction of matrix metalloproteinase (MMP) and Slug protein expression, and inhibition of the production of reactive oxygen species (ROS). Furthermore, evidence is emerging that shows that ROS induced by radiation could increase Met activation. Following on these reports of SAC and Met, we investigated whether SAC could suppress Met activation. MATERIALS AND METHODS: Wound healing, invasion, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium (MTT), soft agar colony forming, western blotting, and gelatin zymography assays were performed in the human nasopharyngeal cancer cell lines HNE1 and HONE1 treated with SAC (0, 10, 20, or 40 mM) and hepatocyte growth factor (HGF). RESULTS: This study showed that SAC could suppress the migration and invasion of HNE1 and HONE1 cell lines by inhibiting p-Met. An increase of migration and invasion induced by HGF and its decrease in a dose dependent manner by SAC in wound healing and invasion assays was observed. The reduction of p-Met by SAC was positively correlated with p-focal adhesion kinase (p-FAK) and p-extracellular related kinase (p-ERK in both cell lines). SAC reduced Slug, MMP2, and MMP9 involved in migration and invasion with the inhibition of Met-FAK signaling. CONCLUSION: These results suggest that SAC inhibited not only Met activation but also the downstream FAK, Slug, and MMP expression. Finally, SAC may be a potent anticancer compound for nasopharyngeal cancer treated with radiotherapy.
Agar
;
Blotting, Western
;
Cadherins
;
Cell Line
;
Emigration and Immigration
;
Gastropoda
;
Gelatin
;
Hepatocyte Growth Factor*
;
Hepatocytes*
;
Humans
;
Nasopharyngeal Neoplasms*
;
Phosphotransferases
;
Radiotherapy
;
Reactive Oxygen Species
;
Wound Healing